Filing Flows › Comparisons › MAZE vs RXRX
Maze Therapeutics vs Recursion Pharmaceuticals: MAZE and RXRX compared
Maze Therapeutics is the larger company: $20.0M of revenue in its latest quarter (Q1 2026) against $18.6M for Recursion Pharmaceuticals (Q3 2026). Maze Therapeutics is more profitable, with an operating margin of -132.8% against -663.9%.
Where the money goes: MAZE and RXRX
Maze Therapeutics (MAZE) · Q1 2026
Maze Therapeutics, Q1 2026: revenue $20.0M, operating margin -132.8%, net loss $24.2M, operating cash flow −$39.1M. The chart follows the revenue to costs, profit and cash.
Recursion Pharmaceuticals (RXRX) · Q3 2026
Recursion Pharmaceuticals, Q3 2026: revenue $18.6M (+258% year over year), operating margin -663.9%, net loss $119M, operating cash flow −$77.4M. The chart follows the revenue to costs, profit and cash.
| Maze Therapeutics (MAZE) | Recursion Pharmaceuticals (RXRX) | |
|---|---|---|
| Latest quarter | Q1 2026 | Q3 2026 |
| Revenue | $20.0M | $18.6M |
| Revenue growth, Y/Y | — | +258% |
| Operating margin | -132.8% | -663.9% |
| Net earnings | −$24.2M | −$119M |
| Net margin | -121.0% | -641.6% |
| Operating cash flow | −$39.1M | −$77.4M |
Where the revenue comes from
Recursion Pharmaceuticals
- Operating revenue: $18.1M (97%)
- Grant revenue: $497K (3%)
Questions
Which is bigger, Maze Therapeutics or Recursion Pharmaceuticals?
Maze Therapeutics is the larger company: $20.0M of revenue in its latest quarter (Q1 2026) against $18.6M for Recursion Pharmaceuticals (Q3 2026).
Is Maze Therapeutics or Recursion Pharmaceuticals growing faster?
Maze Therapeutics is more profitable, with an operating margin of -132.8% against -663.9%.
More: Maze Therapeutics earnings · how Maze Therapeutics makes money · Recursion Pharmaceuticals earnings · how Recursion Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 12, 2026; 10-Q filed Nov 2, 2026). Fiscal quarters can end on different dates. Not investment advice.